AE Incidence Among 68 Patients with Unresectable Advanced PPGL Who Received Any Therapeutic Dose of HSA 131I-MIBG
| AE by preferred term | Treatment-related AE, all grades | Treatment-related AE, grades 3–5 | Any AE, all grades |
| Nausea | 52 (76) | 1 (1) | 53 (78) |
| Thrombocytopenia | 49 (72) | 28 (41) | 49 (72) |
| Anemia | 40 (59) | 14 (21) | 43 (63) |
| Leukopenia | 41 (60) | 28 (41) | 41 (60) |
| Fatigue | 32 (47) | 7 (10) | 41 (60) |
| Neutropenia | 39 (57) | 26 (38) | 39 (57) |
| Vomiting | 33 (49) | 1 (1) | 36 (53) |
| Dry mouth | 27 (40) | 0 | 28 (41) |
| Dizziness | 16 (24) | 1 (1) | 27 (40) |
| Headache | 15 (22) | 0 | 21 (31) |
| Hypotension | 8 (12) | 1 (1) | 18 (26) |
| Decreased appetite | 14 (21) | 1 (1) | 17 (25) |
| Diarrhea | 11 (16) | 2 (3) | 16 (24) |
| Constipation | 4 (6) | 1 (1) | 16 (24) |
Data are numbers followed by percentages in parentheses.
Grade 1 = mild AE; grade 2 = moderate AE; grade 3 = severe AE; grade 4 = life-threatening or disabling AE; grade 5 = death related to AE.